Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    NOTICE OF INTENT - NUCLEIC ACID–BASED REAGENTS FOR IN VIVO TRANSIENT PROTEIN EXPRESSION

    Sol. NIH-26-006363-IntentNoticePresolicitationROCKVILLE, MD
    Closed
    STATUS
    Closed
    closed Feb 14, 2026
    POSTED
    Jan 30, 2026
    Publication date
    NAICS CODE
    325413
    Primary industry classification
    PSC CODE
    6550
    Product & service classification

    AI Summary

    The Department of Health and Human Services intends to award a sole-source contract for nucleic acid-based reagents for in vivo transient protein expression to the University of Pennsylvania. These reagents will be used in preclinical studies to investigate preventive strategies against viral infections, ensuring consistency with previous studies.

    Contract details

    Solicitation No.
    NIH-26-006363-IntentNotice
    Notice Type
    Presolicitation
    Posted Date
    January 30, 2026
    Response Deadline
    February 14, 2026
    NAICS Code
    325413AI guide
    PSC / Class Code
    6550
    Primary Contact
    Ivan Mora-Juarez
    State
    MD
    ZIP Code
    20857
    AI Product/Service
    product

    Description

    This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. 

    Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.

    ------------------------------------------------------------------------------------------------------------------------

    The intent is to award a contract on a solesource basis for Nucleic acid–based reagents for in vivo transient protein expression for the National Cancer Institute and Center for Cancer Research to: 

    Trustees of The University of Pennsilvania - Penn Medicine

    3451 Walnut Street

    Philadelphia, PA

    19104, USA

    The supplies required are nucleic acid-based reagents. 

    The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.

    Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier  for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.

    Key dates

    1. January 30, 2026Posted Date
    2. February 14, 2026Proposals / Responses Due

    AI search tags

    Frequently asked questions

    NOTICE OF INTENT - NUCLEIC ACID–BASED REAGENTS FOR IN VIVO TRANSIENT PROTEIN EXPRESSION is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.